PL
REGN icon

Parkwood LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

Parkwood LLC’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-597
Closed -$293K – 356
2017
Q2 		$293K Buy
+597
New +$261K 0.04% 306
2016
Q3 		– Sell
-634
Closed -$221K – 519
2016
Q2 		$221K Hold
634
– – 0.04% 421
2016
Q1 		$229K Sell
634
-704
-53% -$290K 0.04% 442
2015
Q4 		$726K Hold
1,338
– – 0.11% 107
2015
Q3 		$622K Buy
+1,338
New +$719K 0.1% 120
2014
Q3 		– Sell
-809
Closed -$229K – 299
2014
Q2 		$229K Buy
+809
New +$240K 0.05% 121
2014
Q1 		– Sell
-566
Closed -$156K – 377
2013
Q4 		$156K Buy
+566
New +$163K 0.04% 301

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Parkwood LLC's REGN Position: Q3 2017 in Review

Parkwood LLC sold out of Regeneron Pharmaceuticals (REGN) in Q3 2017, closing a stake of 597 shares — an estimated $293K sold.

Parkwood LLC first reported a position in REGN in Q4 2013 and held it in 7 quarters. The position peaked at $726K in Q4 2015. 606 funds tracked by Wall St. Rank hold REGN as of Q3 2017.

  • Parkwood LLC reported no remaining Regeneron Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Parkwood LLC sold 597 Regeneron Pharmaceuticals shares in Q3 2017, an estimated $293K.
  • Parkwood LLC first reported a position in Regeneron Pharmaceuticals in Q4 2013 and held it in 7 quarters.
  • Parkwood LLC's Regeneron Pharmaceuticals position peaked at $726K in Q4 2015.
  • 606 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2017.

Based on Parkwood LLC's 13F filing for Q3 2017, filed 1 Nov 2017.